NO and PGI2 in coronary endothelial dysfunction in transgenic mice with dilated cardiomyopathy

Basic Research in Cardiology

Volumn 103, Issue 5, 2008, Pages 417-430

  Drelicharz, Lukasz ^a   Kozlovski, Valery ^a   Skorka, Tomasz ^b   Heinze Paluchowska, Sylwia ^b   Jasinski, Andrzej ^b   Gebska, Anna ^a   Guzik, Tomasz ^a   Olszanecki, Rafal ^a   Wojnar, Leszek ^c   Mende, Ulrike ^d   Csanyi, Gabor ^a   Chlopicki, Stefan ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF NUCLEAR PHYSICS   (Poland)

^c CRACOW UNIVERSITY OF TECHNOLOGY   (Poland)

^d BROWN UNIVERSITY   (United States)

Author keywords

Dilated cardiomyopathy; Endothelial dysfunction; Heart failure; Nitric oxide; Prostacyclin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLCHOLINE; APOCYNIN; BRADYKININ; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OXIPURINOL; OXYGEN; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; ROFECOXIB; ROTENONE; SUPEROXIDE; TIRON;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DISEASE COURSE; DISEASE MODEL; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART FAILURE; HEART FUNCTION; IN VIVO STUDY; ISOLATED HEART; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASODILATATION;

6-KETOPROSTAGLANDIN F1 ALPHA; AGE FACTORS; ANIMALS; CARDIOMYOPATHY, DILATED; CORONARY ARTERY DISEASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HEART FAILURE; INTRAMOLECULAR OXIDOREDUCTASES; MEMBRANE PROTEINS; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MYOCARDIUM; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SUPEROXIDES; VASODILATION;

EID: 50249168743     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00395-008-0723-2     Document Type: Article

References (52)

1. Aubin MC, Gendron ME, Lebel V, Thorin E, Tardif JC, Carrier M, Perrault LP (2007) Alterations in the endothelial G-protein coupled receptor pathway in epicardial arteries and subendocardial arterioles in compensated left ventricular hypertrophy. Basic Res Cardiol 102:144-153
2. Bauersachs J, Schafer A (2004) Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Curr Vasc Pharmacol 2:115-124
3. Bell JP, Mosfer SI, Lang D, Donaldson F, Lewis MJ (2001) Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol Heart Circ Physiol 281:H1704-H1710
4. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM (1997) Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100:2189-2195
5. Chlopicki S, Kozlovski VI, Lorkowska B, Drelicharz L, Gebska A (2005) Compensation of endothelium-dependent responses in coronary circulation of eNOS-deficient mice. J Cardiovasc Pharmacol 46:115-123
6. Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, DuBois NB, Ashton AW, Latif F, Jorde UP, Ware JA, LeJemtel TH (2005) Endothelial cell activation in patients with decompensated heart failure. Circulation 111:58-62
7. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW (1997) Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94:8121-8126
8. Delgado RM III, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK, Aleksic N, Sivasubramanian N, McKay K, Mann DL, Willerson JT (2004) Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 109:1428-1433
9. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108:585-590
10. Ermert L, Ermert M, Goppelt-Struebe M, Walmrath D, Grimminger F, Steudel W, Ghofrani HA, Homberger C, Duncker H, Seeger W (1998) Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol 18:479-488
11. FitzGerald GA, Smith B, Pedersen AK, Brash AR (1984) Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 310:1065-1068
12. Flood A, Headrick JP (2001) Functional characterization of coronary vascular adenosine receptors in the mouse. Br J Pharmacol 133:1063-1072
13. Godecke A, Heinicke T, Kamkin A, Kiseleva I, Strasser RH, Decking UK, Stumpe T, Isenberg G, Schrader J (2001) Inotropic response to beta-adrenergic receptor stimulation and anti-adrenergic effect of ACh in endothelial NO synthase-deficient mouse hearts. J Physiol 532:195-204
14. Godecke A, Ziegler M, Ding Z, Schrader J (2002) Endothelial dysfunction of coronary resistance vessels in apoE-/- mice involves NO but not prostacyclin-dependent mechanisms. Cardiovasc Res 53:253-262
15. Godecke A, Decking UKM, Ding Z, Hirchenhain J, Bidmon HJ, Godecke S, Schrader J (1998) Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res 82:186-194
16. Greenberg SS, Ouyang J, Zhao X, Giles TD (1998) Human and rat neutrophils constitutively express neural nitric oxide synthase mRNA. Nitric Oxide 2:203-212
17. Gwozdz P, Drelicharz L, Kozlovski VI, Chlopicki S (2007) Prostacyclin, but not NO, is the major mediator of acetylcholine-induced vasodilatation in the isolated mice heart. Pharmacol Rep 59:545-552
18. Hecker G, Utz J, Kupferschmidt RJ, Ullrich V (1991) Low levels of hydrogen peroxide enhance platelet aggregation by cyclooxygenase activation. Eicosanoids 4:107-113
19. Heinze-Paluchowska S, Skorka T, Drelicharz L, Chlopicki S, Jasiński A (2006) MR imaging of mouse heart in vivo using a specialized probehead and gradient system. Pol J Chem 80:1133-1139
20. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164-2171
21. Jacoby C, Molojavyi A, Flogel U, Merx MW, Ding Z, Schrader J (2006) Direct comparison of magnetic resonance imaging and conductance microcatheter in the evaluation of left ventricular function in mice. Basic Res Cardiol 101:87-95
22. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP (2004) gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109:1795-1801
23. Kanzaki H, Nakatani S, Yamada N, Urayama S, Miyatake K, Kitakaze M (2006) Impaired systolic torsion in dilated cardiomyopathy: Reversal of apical rotation at mid-systole characterized with magnetic resonance tagging method. Basic Res Cardiol 101:465-470
24. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A (2005) Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111:310-314
25. Khush KK, Waters DD (2006) Effects of statin therapy on the development and progression of heart failure: Mechanisms and clinical trials. J Card Fail 12:664-674
26. Kulmacz RJ, Wang LH (1995) Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem 270:24019-24023
27. Kuroedov A, Cosentino F, Luscher TF (2004) Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 22:155-168
28. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A (1991) Simplified mammalian DNA isolation procedure. Nucleic Acids Res 19:4293
29. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM (2002) Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40:477-484
30. Li Y, Zhu H, Kuppusamy P, Roubaud V, Zweier JL, Trush MA (1998) Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem 273:2015-2023
31. Linke A, Recchia F, Zhang X, Hintze TH (2003) Acute and chronic endothelial dysfunction: Implications for the development of heart failure. Heart Fail Rev 8:87-97
32. Lygate CA, Schneider JE, Hulbert K, ten HM, Sebag-Montefiore LM, Cassidy PJ, Clarke K, Neubauer S (2006) Serial high resolution 3D-MRI after aortic banding in mice: Band internalization is a source of variability in the hypertrophic response. Basic Res Cardiol 101:8-16
33. MacCarthy PA, Shah AM (2003) Oxidative stress and heart failure. Coron Artery Dis 14:109-113
34. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ (1998) Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 95:13893-13898
35. Mende U, Semsarian C, Martins DC, Kagen A, Duffy C, Schoen FJ, Neer EJ (2001) Dilated cardiomyopathy in two transgenic mouse lines expressing activated G protein alpha(q): Lack of correlation between phospholipase C activation and the phenotype. J Mol Cell Cardiol 33:1477-1491
36. Munzel T, Harrison DG (1999) Increased superoxide in heart failure: A biochemical baroreflex gone awry. Circulation 100:216-218
37. Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D, Losano G, Pagliaro P (2006) Post-conditioning reduces infarct size in the isolated rat heart: Role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 101:168-179
38. Pratico D, Cyrus T, Li H, FitzGerald GA (2000) Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 96:3823-3826
39. Rebsamen MC, Capoccia R, Vallotton MB, Lang U (2003) Role of cyclooxygenase 2, p38 and p42/44 MAPK in the secretion of prostacyclin induced by epidermal growth factor, endothelin-1 and angiotensin II in rat ventricular cardiomyocytes. J Mol Cell Cardiol 35:81-89
40. Saito T, Giaid A (1999) Cyclooxygenase-2 and nuclear factor-kappaB in myocardium of end stage human heart failure. Congest Heart Fail 5:222-227
41. Saito T, Maehara K, Tamagawa K, Oikawa Y, Niitsuma T, Saitoh S, Maruyama Y (2002) Alterations of endothelium-dependent and -independent regulation of coronary blood flow during heart failure. Am J Physiol Heart Circ Physiol 282:H80-H86
42. Schildknecht S, Bachschmid M, Ullrich V (2005) Peroxynitrite provides the peroxide tone for PGHS-2-dependent prostacyclin synthesis in vascular smooth muscle cells. FASEB J 19:1169-1171
43. Shah DJ, Judd RM, Kim RJ (2005) Technology insight: MRI of the myocardium. Nat Clin Pract Cardiovasc Med 2:597-605
44. Shizukuda Y, Buttrick PM (2002) Oxygen free radicals and heart failure: new insight into an old question. Am J Physiol Lung Cell Mol Physiol 283:L237-L238
45. Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, Xu XB, Kobari Y, Pritchard K Jr, Sessa WC, Hintze TH (1996) Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 78:58-64
46. Tanner FC, van der Loo B, Shaw S, Greutert H, Bachschmid MM, Berrozpe M, Rozenberg I, Blau N, Siebenmann R, Schmidli J, Meyer P, Luscher TF (2007) Inactivity of nitric oxide synthase gene in the atherosclerotic human carotid artery. Basic Res Cardiol 102:308-317
47. Tentolouris C, Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Trikas A, Toutouzas P, Stefanadis C (2004) Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int J Cardiol 94:301-305
48. Uracz W, Gebska A, Ziemianin B, Chlopicki S, Gryglewski RJ (1998) Role of nitric oxide synthase types II and III in early protection against endotoxin-induced lung injury. Exp Clin Cardiol 3:78-86
49. Wiesmann F, Ruff J, Engelhardt S, Hein L, Dienesch C, Leupold A, Illinger R, Frydrychowicz A, Hiller KH, Rommel E, Haase A, Lohse MJ, Neubauer S (2001) Dobutamine-stress magnetic resonance microimaging in mice: Acute changes of cardiac geometry and function in normal and failing murine hearts. Circ Res 88:563-569
50. Wong SCY, Fukuchi M, Melnyk P, Rodger I, Giaid A (1998) Induction of cyclooxygenase-2 and activation of nuclear factor-{kappa}B in myocardium of patients with congestive heart failure. Circulation 98:100-103
51. Wu KK (1998) Cyclooxygenase-2 induction in congestive heart failure: friend or foe? Circulation 98:95-96
52. Yu H, Gallagher AM, Garfin PM, Printz MP (1997) Prostacyclin release by rat cardiac fibroblasts: Inhibition of collagen expression. Hypertension 30:1047-1053